Mhairi Copland, MBChB, PhD, University of Glasgow, Glasgow, UK, suggests that patients with CML who respond to TKI therapy but experience bothersome side effects affecting quality of life may benefit from a lower dosage. The lower dosage may alleviate the side effects, which can in turn increase treatment compliance.